A Review of the Totality of Evidence Supporting the Development of the First Adalimumab Biosimilar ABP 501

ABP 501 [United States: AMJEVITA™ (adalimumab-atto); European Union: AMGEVITA(®) (adalimumab)] is the first approved biosimilar to adalimumab [reference product (RP)], a monoclonal antibody (mAb) targeting tumor necrosis factor-alfa (TNF-α). ABP 501 has received approval for use in indications that...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Adv Ther
Main Authors: Markus, Richard, McBride, Helen J., Ramchandani, Monica, Chow, Vincent, Liu, Jennifer, Mytych, Dan, Fanjiang, Gary
Formato: Artigo
Idioma:Inglês
Publicado: Springer Healthcare 2019
Assuntos:
Review
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC6822859/
https://ncbi.nlm.nih.gov/pubmed/31183781
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s12325-019-00979-6
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares